Acquired Resistance to EGFR-TKI in the Uncommon EGFR Mutation, G719S

被引：0
|
作者：
Osoegawa, A. [1 ]
Hashimoto, T. [1 ]
Takumi, Y. [1 ]
Kobayashi, R. [1 ]
Miyawaki, M. [1 ]
Takeuchi, H. [1 ]
Okamoto, T. [1 ]
Sugio, K. [1 ]
机构：
[1] Oita Univ, Fac Med, Dept Thorac & Breast Surg, Yufu, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Acquired resistance; EGFR-TKI; PTEN;
D O I：
10.1016/j.jtho.2017.09.1568
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02-039
引用
收藏
页码：S2251 / S2251
页数：1
相关论文
共 50 条
  • [21] SLK Causes Resistance to EGFR-TKI in Lung Cancer
    Ashraf, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2371 - S2372
  • [22] Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
    Cao, Peijun
    Li, Yongwen
    Shi, Ruifeng
    Yuan, Yin
    Gong, Hao
    Zhu, Guangsheng
    Zhang, Zihe
    Chen, Chen
    Zhang, Hongbing
    Liu, Minghui
    Pan, Zhenhua
    Liu, Hongyu
    Chen, Jun
    FRONTIERS IN CHEMISTRY, 2022, 10
  • [23] ADVANCEMENT IN APPLICATIONS OF QUANTITATIVE DETECTION OF EGFR MUTATION IN PERIPHERAL BLOOD IN THE THERAPEUTIC EVALUATION OF EGFR-TKI
    Zhang, Y.
    Han, Baohui
    RESPIROLOGY, 2011, 16 : 132 - 132
  • [24] Advances in the management of acquired resistance to EGFR-TKI in non-small cell lung cancer
    Fei Zhou
    Caicun Zhou
    OncologyandTranslationalMedicine, 2015, 1 (01) : 20 - 25
  • [25] Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients
    Jiang, Tao
    Li, Aiwu
    Su, Chunxia
    Li, Xuefei
    Zhao, Chao
    Ren, Shengxiang
    Zhou, Caicun
    Zhang, Jun
    ONCOTARGET, 2017, 8 (37) : 62648 - 62657
  • [26] The Importance to Switch from EGFR-TKI to Cytotoxic Chemotherapy for EGFR Mutation-Positive Adenocarcinoma
    Eriguchi, D.
    Okano, T.
    Kawaguchi, Y.
    Maeda, J.
    Hagiwara, M.
    Kakihana, M.
    Kajiwara, N.
    Ohira, T.
    Ikeda, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S876 - S876
  • [27] Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC
    Yang, Shuo
    Mao, Shiqi
    Li, Xuefei
    Zhao, Chao
    Liu, Qian
    Yu, Xiaofei
    Wang, Yan
    Liu, Yiwei
    Pan, Yingying
    Wang, Chunyan
    Gao, Guanghui
    Li, Wei
    Xiong, Anwen
    Chen, Bin
    Sun, Hui
    He, Yayi
    Wu, Fengying
    Chen, Xiaoxia
    Su, Chunxia
    Ren, Shengxiang
    Zhou, Caicun
    LUNG CANCER, 2020, 139 : 133 - 139
  • [28] Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer
    Zhang, Chen
    Cao, Honggang
    Cui, Yanan
    Jin, Shidai
    Gao, Wen
    Huang, Chenjun
    Guo, Renhua
    THORACIC CANCER, 2021, 12 (19) : 2574 - 2584
  • [29] Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients
    Jiang, Tao
    Ren, Shengxiang
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1235 - S1236
  • [30] Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance
    Zhang, Yidan
    Xu, Yingqi
    Xu, Jianlin
    Zhong, Hua
    Xia, Jinjing
    Zhong, Runbo
    CANCER SCIENCE, 2024, : 753 - 763
12345